Invasive fungal infections are a common problem in liver transplant recipients. Winston et al. performed a randomized, double-blind trial of anidulafungin versus fluconazole in 200 high-risk liver transplant recipients. Both drugs were well tolerated, and graft rejection, fungal-free survival and mortality were similar in both groups. However, anidulafungin was associated with less Aspergillus colonization, and with fewer breakthrough invasive fungal infections in patients who had received pretransplant fluconazole.
References
Winston, D. J. et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am. J. Transplant. 10.1111/ajt.12963
Rights and permissions
About this article
Cite this article
Randomized trial of two antifungal prophylaxis treatments in liver transplant recipients. Nat Rev Gastroenterol Hepatol 12, 2 (2015). https://doi.org/10.1038/nrgastro.2014.212
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.212